Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 95 recruiting now early-phase tilt #43 of 28,707 conditions

Sickle Cell Disease: early-phase trial registry

95 of 214 indexed Sickle Cell Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #43 of 28,707 conditions by registered trial count.

214 US clinical trials · 95 currently recruiting · #43 of 28,707 conditions by registered trial count

Sickle Cell Disease: 214 US clinical trials tracked, 95 recruiting.

Sickle Cell Disease is the subject of 214 registered US clinical trials on ClinicalTrials.gov, 95 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 17 of these trials.

Enrollment posture brief

Registry condition sickle-cell-disease

OPEN 95 | RECR 44% | LATE 14 | EARLY 87 | RANK #43 | SPON 17

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Mild Cognitive Impairment48.5%Sickle Cell Disease (this)44%Atrial Fibrillation29.4%Coronary Artery Disease25.9%Diabetes Mellitus23.3%
Open-enrollment share among volume-matched conditions near Sickle Cell Disease

Sickle Cell Disease lists 95 open slots (44% of 214 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sickle Cell Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sickle Cell Disease is recruiting above its size-band peers.

    95 of 214 indexed trials (44.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Sickle Cell Disease trials is spread across many organizations.

    St. Jude Children's Research Hospital accounts for 17 of 214 trials (7.9%). 101 distinct sponsors appear on at least one study for this condition label.

  3. Most Sickle Cell Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 214 trials that report a genuine target (sentinel values excluded). 150 of those (70.1%) plan for fewer than 100 participants.

  4. Sickle Cell Disease research is mostly interventional.

    160 interventional and 54 observational studies make up this index (74.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 139Phase 248Phase 311Phase 43

Open and recent trials

214 total, page 5 of 5

COMPLETED Phase 2 20 participants

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

NCT01049854

COMPLETED 20 participants

Multi-Center Study of Iron Overload: Pilot Study

UCSF Benioff Children's Hospital Oakland

NCT01114776

COMPLETED NA 18 participants

Cognitive Rehabilitation in Sickle Cell Disease

Duke University

NCT01793740

COMPLETED Phase 1 17 participants

Hydroxyurea and EPO in Sickle Cell Disease

Julia Xu

NCT05451940

COMPLETED NA 15 participants

HRV-B for Symptom Management in Sickle Cell Patients

Prisma Health-Upstate

NCT03383913

COMPLETED Phase 2 13 participants

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

Johns Hopkins University

NCT00940901

COMPLETED Phase 2 10 participants

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Emory University

NCT02757885

COMPLETED 7 participants

Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD

Emory University

NCT00228631

COMPLETED NA 7 participants

Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant

University of Michigan

NCT03458897

COMPLETED Phase 1 7 participants

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Sangamo Therapeutics

NCT03653247

COMPLETED 6 participants

Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease

Oregon Health and Science University

NCT01294891

COMPLETED Phase 2 5 participants

Nitrous Oxide Analgesia Vaso-occlusive Crisis

Columbia University

NCT01891812

COMPLETED Phase 1 4 participants

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Case Comprehensive Cancer Center

NCT02065596

COMPLETED Phase 2 2 participants

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Dana-Farber Cancer Institute

NCT00153985

← Previous Page 5 of 5

Phase Distribution

PhaseTrial count
Phase 1 39
Phase 2 48
Phase 3 11
Phase 4 3

Named interventions

Most-linked intervention names on Sickle Cell Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
15 trials
Alemtuzumab Drug
10 trials
Fludarabine Drug
7 trials
Sirolimus Drug
5 trials
Cyclophosphamide Drug
5 trials
Hydroxyurea Drug
4 trials
Pentostatin Drug
3 trials
Total Body Irradiation Radiation
3 trials

US sites by state

Facility locations filed on Sickle Cell Disease trials. A trial with sites in several states counts in each.

California 41 trials
Illinois 39 trials
Georgia 39 trials
New York 37 trials
Tennessee 36 trials
Maryland 35 trials
North Carolina 34 trials
Ohio 27 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sickle Cell Disease page

214 registered trials, 95 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Disease condition card totals 214 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.